Anlon Healthcare IPO
IPO Listing Details
- Listing Date
03 Sep 2025
- Listing Price
₹91.00
- Listing Change
0.00%
- Last Traded Price
₹148.25
Anlon Healthcare IPO Details
-
Open Date
26 Aug 2025
-
Close Date
29 Aug 2025
-
Listing Date
03 Sep 2025
- IPO Price Range
₹ 86 to ₹91
- IPO Size
₹ 121.03 Cr
- Listing Exchange
BSE NSE
Anlon Healthcare IPO Timeline
Anlon Healthcare IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 26-Aug-25 | 0.91 | 0.71 | 8.99 | 1.69 |
| 28-Aug-25 | 1.01 | 2.09 | 22.33 | 3.30 |
| 29-Aug-25 | 1.07 | 10.56 | 46.43 | 7.03 |
Last Updated: 29 September 2025 2:53 PM by 5paisa
Anlon Healthcare Limited, launching a ₹ 121.03 Cr IPO, specialises in manufacturing high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for medicines, nutraceuticals, personal care, and veterinary products. Operating under global pharmacopeia standards (IP, BP, EP, JP, USP), it also provides custom synthesis of complex chemicals to meet client-specific purity needs. The company has filed 21 DMFs globally, with approvals from ANVISA, NMPA, and PMDA, and is pursuing Ketoprofen and Dexketoprofen Trometamol. Its portfolio spans 65 commercial products, 28 pilot-stage, and 49 under lab testing, supported by advanced labs and a skilled scientific team.
Established in: 2013
Managing Director: Mr. Punitkumar R. Rasadia
Peers
| Metric | Kronox Lab Sciences Limited | AMI Organics Limited | Supriya Lifesciences Limited |
| CMP | 149.85 | 2,354.55 | 732.95 |
| EPS | 5.81 | 11.91 | 14.80 |
| PE Ratio | 26.72 | 197.70 | 49.52 |
| RON W (%) | 32.20 | 6.47 | 14.61 |
| NAV(Per Share) | 17.87 | 183.05 | 101.31 |
| Face Value | 10.00 | 10.00 | 2.00 |
| Revenue from Operation | 8,686.24 | 68,758.29 | 57,037.00 |
| Other Income | 157.79 | 1,378.58 | 1,063.50 |
| Total Income | 9,144.03 | 70,136.87 | 58,100.50 |
Anlon Healthcare Objectives
● The company will fund capital expenditure of about ₹307.20 crore for the proposed expansion.
● It will repay or prepay certain outstanding secured borrowings of around ₹50.00 crore.
● About ₹431.50 crore will be utilized to meet working capital requirements.
● The balance will be used for general corporate purposes.
Anlon Healthcare IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹121.03 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹121.03 Cr |
Anlon Healthcare IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | 14,104 |
| Retail (Max) | 13 | 2,132 | 1,83,352 |
| S-HNI (Min) | 14 | 2,296 | 1,97,456 |
| S-HNI (MAX) | 67 | 10,988 | 9.44,968 |
| B-HNI (Min) | 68 | 11,152 | 9,59,072 |
Anlon Healthcare IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB | 1.07 | 99,75,000 | 1,06,89,028 | 97.27 |
| NII (HNI) | 10.56 | 19,95,000 | 2,10,66,456 | 191.70 |
| Retail | 46.43 | 13,30,000 | 6,17,55,184 | 561.97 |
| Total** | 7.03 | 1,33,00,000 | 9,35,10,668 | 850.95 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (in Rs. Crores) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 113.12 | 66.69 | 77.37 |
| EBITDA | 12.41 | 15.46 | 17.36 |
| PAT | 5.82 | 9.66 | 11.96 |
| Particulars (in Rs. Crores)] | FY23 | FY24 | FY25 |
|---|---|---|---|
| Total Assets | 111.55 | 128 | 160.96 |
| Share Capital | 12.00 | 16.00 | 39.85 |
| Total Borrowings | 66.39 | 74.56 | 62.39 |
| Particulars (in Rs. Crores | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | -2.49 | -3.23 | -27.22 |
| Net Cash Generated From / (used in) investing activities | -0.33 | -3.37 | -2.82 |
| Net Cash Generated From / (used in) financing activities | 2.27 | 8.25 | 23.59 |
| Net Increase (Decrease) In Cash And Cash Equivalents | -0.92 | 1.65 | -0.81 |
Strengths
1. Strong portfolio of APIs and intermediates.
2. Global DMF approvals enhance market credibility.
3. Skilled scientific team ensures quality assurance.
4. Custom manufacturing capability for complex chemicals.
Weaknesses
1. High dependence on regulatory approvals globally.
2. Limited brand visibility in the competitive pharma market.
3. Significant capital required for product expansions.
4. Reliance on specific APIs for revenue streams.
Opportunities
1. Rising demand for APIs in global markets.
2. Expansion into nutraceuticals and personal care segments.
3. Growing outsourcing opportunities for custom synthesis.
4. Increasing demand for cost-effective quality pharmaceuticals.
Threats
1. Intense competition from established API manufacturers.
2. Fluctuating raw material costs affect margins.
3 Stringent global regulatory compliance requirements.
4. Currency exchange risks in export-driven revenues.
1. Diversified portfolio across APIs, intermediates, and nutraceuticals.
2. Strong regulatory approvals enhance global market presence.
3. Expansion plans aimed at accelerating future growth.
4. Experienced scientific team ensures consistent product quality.
Anlon Healthcare operates in the growing pharmaceutical API and intermediates market, supported by increasing global demand for cost-effective, high-quality medicines, nutraceuticals, and personal care products. With approvals from key regulatory authorities and a pipeline of products under development, the company is well-positioned to expand its portfolio, strengthen exports, and capture emerging opportunities in custom chemical manufacturing. Its focus on innovation and quality ensures long-term growth potential.
- Companies
- Type
- Opening On
-
Wakefit Innovations
- Mainboard
- 08th Dec
- Pre-Book
-
Corona Remedies
- Mainboard
- 08th Dec
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Anlon Healthcare IPO opens from August 26, 2025 to August 29, 2025.
The size of Anlon Healthcare IPO is ₹121.03 Cr.
The price band of Anlon Healthcare IPO is fixed at ₹86 to ₹91 per share.
To apply for Anlon Healthcare IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Anlon Healthcare IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Anlon Healthcare IPO is of 2 lots consisting of 164 shares and the investment required is ₹14,104.
The share allotment date of Anlon Healthcare IPO is September 1, 2025
The Anlon Healthcare IPO will likely be listed on September 3, 2025.
Interactive Financial Services Ltd is the book running lead manager for Anlon Healthcare IPO.
Anlon Healthcare plans to utilise the raised capital from the IPO for:
● The company will fund capital expenditure of about ₹307.20 crore for the proposed expansion.
● It will repay or prepay certain outstanding secured borrowings of around ₹50.00 crore.
● About ₹431.50 crore will be utilized to meet working capital requirements.
● The balance will be used for general corporate purposes.
Anlon Healthcare Contact Details
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: https://www.anlon.in/
Anlon Healthcare IPO Register
Interactive Financial Services Ltd.
Anlon Healthcare IPO Lead Manager
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: ahl.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/